Zymeworks EVP Adam Schayowitz sells $357,557 in ZYME stock for taxes

Executive Vice President and Head of Research & Development at Zymeworks Inc., Adam Schayowitz, sold 13,832 shares of the company's common stock on October 9, 2026, amounting to $357,557 to cover tax obligations. This sale, which occurred upon the vesting of restricted stock units (RSUs), was a mandatory transaction and not a discretionary one.

The shares were sold at prices ranging from $25.85 to $25.88, with a weighted average price of $25.85 per share. Despite the recent sale, Zymeworks remains an attractive investment according to analysts, who maintain a bullish outlook on the company with price targets ranging from $32 to $60. The stock currently trades at $25.79, up 42.8% over the past year.

Other recent developments include Zymeworks' acquisition of Theravance Biopharma, which has received positive evaluations from investment firms, and FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.